• Explore /
  • Poster
  • / A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.

A two-part phase 2 randomized study of dalantercept and axitinib versus placebo plus axitinib in advanced renal cell carcinoma: Results from the part 1 dose escalation cohorts.

Abstract Poster

Authors

Michael Atkins

Michael B. Atkins

Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

Michael B. Atkins , Martin Henner Voss , Elizabeth R. Plimack , Brian I. Rini , Robert Alter , Nancy Ann Dawson , J. Thaddeus Beck , Rupal Satish Bhatt , Kristen M. Pappas , Dawn Wilson , Ty McClure , Ravi Kumar , Kenneth M. Attie , Matthew L. Sherman , Shuchi Sumant Pandya

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT01727336

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 4566)

DOI

10.1200/jco.2014.32.15_suppl.4566

Abstract #

4566

Poster Bd #

134

Abstract Disclosures

Similar Posters

First Author: Martin Henner Voss

First Author: Martin Henner Voss

First Author: Martin Henner Voss

First Author: Toni K. Choueiri